Mindfulness in Motion Targeted to Sustaining the Mental and Physical Resilience of First Responders

June 14, 2026 updated by: Maryanna Klatt, Ohio State University
High levels of chronic and recurrent workplace stress can profoundly impact the physical, mental, and emotional health of first responders. A multi-modal evidence-based mindfulness intervention was delivered to cohorts of first responders to evaluate effects on perceived stress, resilience, work engagement, and musculoskeletal pain.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The occupational stress experienced by first responders can result in decreased quality and safety of patient care, increased risk of first responder injury, and decreased organizational performance. Worksite mindfulness interventions have been shown to support decreases in occupational stress, as well as improved resilience and work engagement for other high stress professions. Mindfulness in Motion (MIM), an evidence-based mindfulness intervention, was adapted to target the specific occupational needs of first responders in a format that could be easily integrated into their workdays. Three cohorts of first responders received eight weekly synchronous mindfulness sessions with full access to the companion smartphone MIM app for six months after the core eight-week sessions were completed. Adaptations to the MIM content and experiential practices were informed by first responder feedback prior to the study. Self-report surveys to assess perceived stress, resilience, work engagement, and musculoskeletal pain were completed by first responder participants before participation in the intervention, at the end of the eight week intervention, and again six months after the intervention was completed.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
29

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Ohio
      • Columbus, Ohio, United States, 43210
        • The Ohio State University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Actively working as a community First Responder
  • 18 years or older
  • Ability to understand and read English
  • Commitment to participation in the eight weekly virtual sessions, download the MIM smartphone app
  • Adequate Wi-Fi to access the MIM app content

Exclusion Criteria:

  • First responder working in a hospital or healthcare setting

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Intervention Group
First responders participate in an eight-week, synchronous virtual mindfulness intervention, during work hours, with access to companion smartphone app to reinforce virtually presented content and support individual mindfulness practices.
Behavioral: Mindfulness in Motion for First Responders
Mindfulness in Motion (MIM) is an eight-week, evidence-based workplace intervention designed to provide participants with practical strategies to reduce stress and burnout, and improve resilience. Offered virtually, MIM was adapted to support first responders relative to their occupational stressors and unique work characteristics. A companion smartphone app supplemented the eight weekly synchronous sessions and offered content informed by first responders and experiential practices that were modeled by first responders.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Perceived Stress Scale (PSS-10)
Time Frame: Baseline, immediately after the 8 week intervention, and 6 months after the completion of the 8-week intervention
The Perceived Stress Scale-10 is a self-report measure of perceived stress that measures the degree to which situations in one's life over the past month are appraised as stressful. The 4-point Likert scale responses are 0=Never, 1=Almost Never, 2=Sometimes, 3=Fairly Often, and 4=Very Often. Individual scores are summed and range from 0 to 40 with higher scores indicating higher perceived stress.
Baseline, immediately after the 8 week intervention, and 6 months after the completion of the 8-week intervention
Connor-Davidson Resilience Scale-10 (CD-RISC-10)
Time Frame: Baseline, immediately after the 8 week intervention, and 6 months after the completion of the 8-week intervention
The Connor Davidson-Resilience Scale-10 is a 10-item self-report assessment of a person's ability to bounce back after adversity. A 5-point Likert scale for each statement ranges from 0=Not true at all to 4=True nearly all of the time. A respondents's total sum score can range from 0-40 with higher scores indicating higher resilience.
Baseline, immediately after the 8 week intervention, and 6 months after the completion of the 8-week intervention
Utrecht Work Engagement Scale-0 (UWES-9)
Time Frame: Baseline, immediately after the 8 week intervention, and 6 months after the completion of the 8-week intervention
A 9-item assessment of attitudes towards one's job. The Utrecht Work Engagement Scale-9 measures three dimensions: dedication, vigor, and absorption. All items are rated on a 7-point Likert scale ranging from 0=Never, 1=Almost Never, 2=Rarely, 3=Sometimes, 4=Often, 5=Very Often, and 6=Always. Each sub scale time is summed and ranges from 0-18. Higher scores for each sub scale indicate higher dedication, vigor, and absorption with work.
Baseline, immediately after the 8 week intervention, and 6 months after the completion of the 8-week intervention

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Modified Nordic Musculoskeletal Questionnaire (mNMQ)
Time Frame: Baseline, immediately after the 8 week intervention, and 6 months after the completion of the 8-week intervention
The Modified Nordic Musculoskeletal Questionnaire is a standardized 14-item tool assessing musculoskeletal symptoms, over the past 12 months and past 7 days, across multiple body regions. Q. 1 asks about musculoskeletal pain in 9 anatomical areas include the neck, shoulders, upper back, elbows, lower back, wrists/hands, hips/thighs, knees, and ankles/feet--yes/no are responses. Q. 2 asks frequency of musculoskeletal issues in the 9 anatomical areas over the past 30 days with Q. 3 asking about length of time related to the musculoskeletal pain and Q. 4 about intensity of the pain that was indicated. With yes/no responses, Q. 5 & 6 asks if pain has interfered with usual activities; question 7 asks if a healthcare provider was seen. Q. 9, 10, 11 asks if work activities have been disrupted and if a formal diagnosis was determined. Q. 12, 13, and 14 asks about related symptoms. The tool uses a structured, forced-choice format supported by a body map. There is no minimum or maximum score.
Baseline, immediately after the 8 week intervention, and 6 months after the completion of the 8-week intervention
Mindfulness in Motion smartphone app usage
Time Frame: Immediately after completion of the 8-week intervention
App usage data in time per participant
Immediately after completion of the 8-week intervention
Mindfulness in Motion videos watched
Time Frame: immediately after completion of the 8-week intervention
Frequency of videos watched by the overall participant sample on the smartphone app
immediately after completion of the 8-week intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ohio State University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Maryanna Klatt, PhD, Ohio State University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 1, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 30, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 19, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 24, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 30, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 16, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 14, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2022B0254

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The de-identified data and analysis code will be submitted to the Dryad repository. Human subjects demographics will be limited to three de-identified descriptors. MIM app usage will be submitted as de-identified usage frequencies. Paired t-test and ANOVA analysis for perceived stress, resilience, and work engagement will be submitted as de-identified, cohort data-comparison on means. nNMQ data will be submitted as frequency and comparison of means.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings